-
Biosimulation is described as computer-aided mathematical simulation of biological processes and systems
-
It is used to test medicines, but without the involvement of any human or animal subjects
UAE-based Mubadala Investment Company has invested approximately $250 million in US-based biosimulation firm Certara, said local reports on Wednesday, July 28.
Biosimulation is described as computer-aided mathematical simulation of biological processes and systems. It is used to test medicines, but without the involvement of any human or animal subjects.
The local reports said the deal happened between Certara, Mubadala, and some existing institutional shareholders of Certara, including a shareholder affiliated with EQT.
They reportedly entered into an agreement under which an affiliate of Mubadala would purchase an aggregate of 9,615,384 shares at $26 per share from the shareholders in a private transaction.
The transaction is scheduled to close on August 2. EQT is expected to remain a significant shareholder in the company after the transaction.
Certara CEO William F Feehery was quoted by the local reports as saying: “As a newly listed public company, we are excited by Mubadala’s recognition of Certara’s performance and position as a global leader in biosimulation, especially as we execute on our next phase of growth.”
Mubadala’s Head of Life Sciences Camilla Languille said, “Biosimulation is transforming traditional drug development via computational approaches that save time and cost throughout the entire biopharma R&D process. We are proud to have invested in Certara.”
